Literature DB >> 6508338

Mycoplasma pneumoniae: acute illness, antibiotics, and subsequent pulmonary function.

A R Sabato, A J Martin, B P Marmion, T W Kok, D M Cooper.   

Abstract

One hundred and eight children presenting with Mycoplasma pneumoniae infection were assessed during the acute illness and followed for three years. The incidence of wheezing with the acute infection (40%) was greater than expected in a normal childhood population. The initial illness precipitated wheezing for the first time in some subjects but others wheezed only with the acute illness. In non-asthmatic subjects significant bronchodilator responsiveness was present one month after infection. Children given erythromycin during the first seven days of their illness had a significantly shorter fever duration compared with those treated inappropriately. No significant effects of treatment were noted on pulmonary function three years later but non-asthmatic children had abnormal mean forced expiratory volume in one second and forced expiratory flow after 50% of the expired vital capacity compared with 64 healthy controls. These findings indicate impaired function three years after initial infection.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6508338      PMCID: PMC1628832          DOI: 10.1136/adc.59.11.1034

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  15 in total

1.  The results of pulmonary function tests in patients infected with Mycoplasma pneumoniae.

Authors:  J P Dierckx; C Gillard
Journal:  Infection       Date:  1976       Impact factor: 3.553

2.  The association of viral and mycoplasma infections with recurrence of wheezing in the asthmatic child.

Authors:  S Berkovich; S J Millian; R D Snyder
Journal:  Ann Allergy       Date:  1970-02

3.  Comparison of antibiotics in the treatment of mycoplasmal pneumonia.

Authors:  J M Shames; R B George; W B Holliday; J R Rasch; W J Mogabgab
Journal:  Arch Intern Med       Date:  1970-04

4.  Mycoplasma pneumoniae infection followed by Haemophilus influenzae pneumonia and bacteremia.

Authors:  B V Stadel; H M Foy; J W Nuckolls; G E Kenny
Journal:  Am Rev Respir Dis       Date:  1975-07

5.  Mycoplasma pneumoniae infections in children.

Authors:  D Stevens; P G Swift; P G Johnston; P J Kearney; B D Corner; D Burman
Journal:  Arch Dis Child       Date:  1978-01       Impact factor: 3.791

6.  Susceptibility of Mycoplasma pneumoniae to 21 antibiotics in vitro.

Authors:  R L Jao
Journal:  Am J Med Sci       Date:  1967-06       Impact factor: 2.378

7.  Studies on an epidemic of respiratory disease caused by Mycoplasma pneumoniae.

Authors:  T Feizi; H Maclean; R G Sommerville; J G Selwyn
Journal:  Br Med J       Date:  1967-02-25

8.  Pulmonary function in children with Mycoplasma pneumoniae pneumonia.

Authors:  B Kjellman
Journal:  Infection       Date:  1976       Impact factor: 3.553

9.  Prevalence, natural history, and relationship of wheezy bronchitis and asthma in children. An epidemiological study.

Authors:  H Williams; K N McNicol
Journal:  Br Med J       Date:  1969-11-08

10.  The etiologic and epidemiologic spectrum of bronchiolitis in pediatric practice.

Authors:  F W Henderson; W A Clyde; A M Collier; F W Denny; R J Senior; C I Sheaffer; W G Conley; R M Christian
Journal:  J Pediatr       Date:  1979-08       Impact factor: 4.406

View more
  16 in total

1.  Evaluation of LBM415 (NVP PDF-713), a novel peptide deformylase inhibitor, for treatment of experimental Mycoplasma pneumoniae pneumonia.

Authors:  Monica Fonseca-Aten; Christine M Salvatore; Asunción Mejías; Ana M Ríos; Susana Chávez-Bueno; Kathy Katz; Ana M Gómez; George H McCracken; R Doug Hardy
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

Review 2.  Asthma in children: are chlamydia or mycoplasma involved?

Authors:  S Esposito; N Principi
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

3.  Secondary bacterial infections in children with proved Mycoplasma pneumoniae.

Authors:  R Staugas; A J Martin
Journal:  Thorax       Date:  1985-07       Impact factor: 9.139

4.  Mycoplasma pneumoniae in children with acute and refractory asthma.

Authors:  Pamela R Wood; Vanessa L Hill; Margaret L Burks; Jay I Peters; Harjinder Singh; Thirumalai R Kannan; Shruthi Vale; Marianna P Cagle; Molly F R Principe; Joel B Baseman; Edward G Brooks
Journal:  Ann Allergy Asthma Immunol       Date:  2013-02-23       Impact factor: 6.347

5.  Elevated cytokine and chemokine levels and prolonged pulmonary airflow resistance in a murine Mycoplasma pneumoniae pneumonia model: a microbiologic, histologic, immunologic, and respiratory plethysmographic profile.

Authors:  R D Hardy; H S Jafri; K Olsen; M Wordemann; J Hatfield; B B Rogers; P Patel; L Duffy; G Cassell; G H McCracken; O Ramilo
Journal:  Infect Immun       Date:  2001-06       Impact factor: 3.441

Review 6.  Mycoplasma pneumoniae and its role as a human pathogen.

Authors:  Ken B Waites; Deborah F Talkington
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

Review 7.  Is asthma an infectious disease? New evidence.

Authors:  T Prescott Atkinson
Journal:  Curr Allergy Asthma Rep       Date:  2013-12       Impact factor: 4.806

8.  Impact of cethromycin (ABT-773) therapy on microbiological, histologic, immunologic, and respiratory indices in a murine model of Mycoplasma pneumoniae lower respiratory infection.

Authors:  Ana María Ríos; Asunción Mejías; Susana Chávez-Bueno; Mónica Fonseca-Aten; Kathy Katz; Jeanine Hatfield; Ana María Gómez; Hasan S Jafri; George H McCracken; Octavio Ramilo; Robert Doug Hardy
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

9.  Infection, eosinophilia and childhood asthma.

Authors:  Chang-Keun Kim; Zak Callaway; Takao Fujisawa
Journal:  Asia Pac Allergy       Date:  2012-01-31

10.  Analysis of pulmonary inflammation and function in the mouse and baboon after exposure to Mycoplasma pneumoniae CARDS toxin.

Authors:  R Doug Hardy; Jacqueline J Coalson; Jay Peters; Adriana Chaparro; Chonnamet Techasaensiri; Angelene M Cantwell; T R Kannan; Joel B Baseman; Peter H Dube
Journal:  PLoS One       Date:  2009-10-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.